

PID Q2 17-18 Performance Delivery

REC No	IRAS No	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial
16/LO/015	193306	A real-world, point of care, randomized, 2-arm, open, 52-week study to evaluate the effect of a digital disease management support tool in patients with type 2 diabetes mellitus	Number Agreed	25	25	Date Agreed	14/10/2016	14	14/10/2016	14	Recruitment Finished
15/EM/024	179169	Effect of Tralokinumab on Airway Inflammation in Asthma	Number Agreed	6	6	Date Agreed	30/11/2016	8	30/11/2016	8	Recruitment Finished
16/EM/000	191553	A 24 week, Multicentre, Randomized, Open Label, 2 ARm Parallel-group study evaluating the Efficacy and Safety of Patient - versus Physician-managed Titration of Insulin Glargine U300 in Type 2 Diabetes Mellitus	Number Agreed	10	10	Date Agreed	01/12/2016	9	01/12/2016	9	Recruitment Finished
15/EM/047	187884	Phase II trial of anetumab ravtansine (BAY 94-9343) in patients with advanced or metastatic malignant pleural mesothelioma (MPM) overexpressing mesothelin after first line treatment with platinum in combination with pemetrexed	Number Agreed	4	4	Date Agreed	16/12/2016	5	16/12/2016	5	Recruitment Finished
15/LO/051	176955	A Multi-arm, Phase 3, Randomized, Placebo Controlled, Double Blind Clinical Trial to Investigate the Efficacy and Safety of BMS-663068 in Heavily Treatment Experienced Subjects Infected with Multi-drug Resistant HIV-1	Number Agreed	2	2	Date Agreed	21/12/2016	0	21/12/2016	0	Recruitment Finished
15/EE/035	187779	A Phase III, randomised, double blind, placebo-controlled, parallel group, efficacy, safety and tolerability trial of once daily, oral doses of Empagliflozin as Adjunctive to inSulin thErapy over 26 weeks in patients with Type 1 Diabetes Mellitus (EASE-3)	Number Agreed	3	3	Date Agreed	21/12/2016	0	21/12/2016	0	Recruitment Finished
15/SC/069	192903	Clinical Study Protocol M13-549A Phase 3, Randomized, double-blind Study Comparing ABT-494 to placebo in subjects with moderately to severely active rheumatoid arthritis who are on a stable dose of conventional synthetic disease-modifying anti-rheumatic dr	Number Agreed	3	3	Date Agreed	22/12/2016	1	22/12/2016	1	Recruitment Finished
13/NE/012	119485	A prospective double blind randomised controlled study to evaluate the immunological benefits and clinical effects of an elimination diet using an amino acid formula (AAF) with an added preprobiotic blend in infants with Cow?s Milk Allergy (CMA).	Number Agreed	1	1	Date Agreed	31/12/2016	2	31/12/2016	2	Recruitment Finished

PID Q2 17-18 Performance Delivery

REC No	IRAS No	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial
15/EM/034	183906	A Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of Amatuximab in Combination with Pemetrexed and Cisplatin in Subjects with Unresectable Malignant Pleural Mesothelioma	Number Agreed	5	5	Date Agreed	13/01/2017	8	13/01/2017	8	Recruitment Finished
11/SC/005	74662	INCA 2201, INC 424 - A Phase IB, Open-Label, Dose-Finding Study Of The JAK-inhibitor INC424 Tablets Administered Orally to Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera-Myelofibrosis (PPV-MF) Or Post-Essential Thrombocythemia-Myelofibro	Number Agreed	2	2	Date Agreed	13/01/2017	0	13/01/2017	0	Recruitment Finished
16/LO/044	198164	A Phase 2 Study of LY2606368 in patients with extensive stage disease small cell lung cancer.	Number Agreed	2	2	Date Agreed	18/01/2017	1	18/01/2017	1	Recruitment Finished
15/NW/01	169540	A multicenter, open-label, single-arm safety study of Herceptin Subcutaneous in combination with Perjeta and Docetaxel in treatment of patients with HER2-Positive advanced breast cancer (metastatic or locally recurrent)	Number Agreed	15	15	Date Agreed	03/02/2017	3	03/02/2017	3	Recruitment Finished
16/NW/01	196447	An open-label, randomised, phase II study comparing TAS-102 plus bevacizumab to capecitabine plus bevacizumab in patients with previously untreated metastatic colorectal cancer who are eligible for non-intensive therapy	Number Agreed	12	12	Date Agreed	27/02/2017	2	27/02/2017	2	Recruitment Finished
16/SC/033	208403	Utilizing Novel dipole density Capabilities to Objectively Visualize the Etiology of Rhythms in Atrial Fibrillation (UNCOVER-AF)	Number Agreed	10	10	Date Agreed	01/03/2017	1	01/03/2017	1	Recruitment Finished
15/LO/150	187068	Investigation of drug-drug interaction between nintedanib and pirfenidone in patients with IPF (an open label, multiple-dose, two group study)	Number Agreed	4	4	Date Agreed	06/03/2017	3	06/03/2017	3	Recruitment Finished
15/NW/04	182025	A Randomized, Multicenter, Open-Label, 3 Arm Phase 3 Study of Obinutuzumab in Combination with Chlorambucil, ACP-196 in Combination with Obinutuzumab, and ACP-196 Monotherapy in Subjects with Previously Untreated Chronic Lymphocytic Leukemia	Number Agreed	3	3	Date Agreed	13/03/2017	3	13/03/2017	3	Recruitment Finished

PID Q2 17-18 Performance Delivery

REC No	IRAS No	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial
09/H0405/	27111	A Randomized Double-blind Placebo-Controlled Trial of Neratinib (HKI-272) After Trastuzumab in Women With Early-Stage HER-2/neu Overexpressed/Amplified Breast Cancer	Number Agreed	10	10	Date Agreed	25/04/2017	5	25/04/2017	5	Recruitment Finished
16/EE/004	192528	A two-arm, randomised, assessor-blind, parallel group study to evaluate the effect of fluticasone/formoterol breath actuated inhaler (BAI) and Relvar Ellipta DPI on ventilation heterogeneity in subjects with partially controlled or uncontrolled asthma	Number Agreed	7	7	Date Agreed	28/04/2017	4	28/04/2017	4	Recruitment Finished
16/LO/145	202124	A Phase 3, Multicenter, Randomized, Double Blind Study of Bortezomib and Dexamethasone in Combination with Either Venetoclax or Placebo in Subjects with Relapsed or Refractory Multiple Myeloma Who are Sensitive or Na?ve to Proteasome Inhibitors	Number Agreed	6	6	Date Agreed	17/05/2017	6	17/05/2017	6	Recruitment Finished
15/LO/123	183416	A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, 2-Arm, Efficacy and Safety Study of NEOD001 Plus Standard of Care vs. Placebo Plus Standard of Care in Subjects with Light Chain (AL) Amyloidosis	Number Agreed	2	2	Date Agreed	18/05/2017	0	18/05/2017	0	Recruitment Finished
16/NW/00	197706	SOLAR-1: A phase III randomized double-blind, placebo-controlled study of alpelisib in combination with fulvestrant for men and post-menopausal women with hormone-receptor positive, HER2-negative advanced breast cancer which progressed on or after aromatase	Number Agreed	8	8	Date Agreed	10/06/2017	3	10/06/2017	3	Recruitment Finished
17/EE/002	221514	A PHASE II, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF MOXR0916 IN COMBINATION WITH ATEZOLIZUMAB VERSUS ATEZOLIZUMAB ALONE IN PATIENTS WITH UNTREATED LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA WHO ARE INELIGIBLE FOR CISPLAT	Number Agreed	5	5	Date Agreed	29/06/2017	0	29/06/2017	0	Recruitment Finished
15/NW/04	181246	A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia	Number Agreed	5	5	Date Agreed	30/06/2017	2	30/06/2017	2	Recruitment Finished

PID Q2 17-18 Performance Delivery

REC No	IRAS No	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial
13/NE/000	100377	Product Surveillance Registry A prospective, noninterventional registry providing continuing evaluation and periodic reporting of product safety, effectiveness and patient outcomes across Medtronic marketreleased products within diabetes, cardiac rhythm di	Number Agreed	5	5	Date Agreed	03/07/2017	3	03/07/2017	3	Recruitment Finished
14/SC/116	155743	Prospective, single-arm, multi-centre, observational registry to further validate safety and efficacy of the ultimaster DES in real-world patients.	Number Agreed	100	100	Date Agreed	10/08/2017	100	10/08/2017	100	Recruitment Finished
15/WA/04	189501	Expanding?MRI?Access?for?Patients?with?New?and?Existing?ICDs?and?CRT-Ds	Number Agreed	10	10	Date Agreed	10/08/2017	10	10/08/2017	10	Recruitment Finished
16/YH/011	198679	Phase 2 Study of the Efficacy and Safety of ACP-196 in Subjects with Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy: ACE-CL-208	Number Agreed	2	2	Date Agreed	21/08/2017	0	21/08/2017	0	Recruitment Finished
14/WM/10	152229	A prospective, multicenter, randomized, double blind, placebo-controlled, 2-parallel groups, phase 3 study to compare the efficacy and safety of masitinib in combination with FOLFIRI (irinotecan, 5-fluorouracil and folinic acid) to placebo in combination wi	Number Agreed	5	5	Date Agreed	01/09/2017	3	01/09/2017	3	Recruitment Finished
16/LO/194	213099	AN OPEN LABEL, SINGLE ARM, MULTICENTER, SAFETY STUDY OF ATEZOLIZUMAB IN LOCALLY ADVANCED OR METASTATIC UROTHELIAL OR NON-UROTHELIAL CARCINOMA OF THE URINARY TRACT	Number Agreed	5	5	Date Agreed	04/09/2017	9	04/09/2017	9	Recruitment Finished
15/SC/070	192904	Clinical Study Protocol M13-549A Phase 3, randomized, double-blind study comparing ABT-494 to placebo in subjects with moderately to severely active rheumatoid arthritis who are on a stable dose of conventional synthetic disease-modifying anti-rheumatic dr	Number Agreed	4	4	Date Agreed	12/09/2017	0	12/09/2017	0	Recruitment Finished
14/WS/114	166537	Multicenter, randomized, double-blind, double-dummy, active-comparator, event-driven, superiority phase III study of secondary prevention of stroke and prevention of systemic embolism in patients with a recent Embolic Stroke of Undetermined Source (ESUS),	Number Agreed	10	10	Date Agreed	20/09/2017	7	20/09/2017	7	Recruitment Finished